急性粒细胞白血病CD33、CD45及MDR表达和靶抗原的筛选  

Expression of CD33, CD45,MDR and selection of targeted antigen in acute myelocytic leukemia patients

作　　者：刘捷[1] 张王刚[1] 柏春梅[1] 陈银霞[1] 曹星梅[1] 

机构地区：[1]西安交通大学第二医院血液内科,西安710004

出　　处：《临床血液学杂志》2004年第1期7-8,共2页Journal of Clinical Hematology

摘　　要：目的 :观察急性粒细胞白血病 (AML)CD33、CD4 5及MDR表达和抗原强度的变化 ,筛选特异的靶抗原 ,探讨抗体靶向治疗的应用价值。方法 :应用间接免疫荧光法检测AML细胞CD33、CD4 5及MDR的表达和抗原强度的变化。结果 :CD33、CD4 5表达阳性率分别为 81.5 %、90 .6 % ,CD33抗原表达比CD4 5强 ,差异有显著性意义(P <0 .0 5 )。CD33与MDR在白血病细胞上表达差异无显著性意义。结论 :CD33特异性强 ,抗原性强 ,适合作靶抗原 ;MDR也是耐药白血病治疗的较好靶抗原。抗体靶向治疗将是AML治疗的一条新途径。Objective:To detect the expression and intensity variety of CD33,CD45,MDR on surface of acute myeloid leukemia cells,investigating the clinical value of specific targeted antigen in antibody targeted therapy.Method:Using indirect immunofluorescence method, the positive rates and antigen intensity variety of CD33, CD45 and MDR were detected in 54 acute myeloid leukemia patients.Result:The positive rates of CD33, CD45 was 81.5 %, 90.6 %, respectively. The expression of CD33 was specific and high in AML patients. the difference was significant.Conclusion:CD33 was an optimum targeted antigen. MDR was a targeted antigen in drug resistance AML. Antibody targeted therapy will be a new pathway in treatment of acute leukemia.

关 键 词：急性粒细胞白血病 肿瘤特异性抗原 多药耐药 抗体靶向治疗 CD33 CD45 MDR 靶抗原 基因表达 

分 类 号：R733.71[医药卫生—肿瘤] R394[医药卫生—临床医学]